Kliknite ovdje ako je ovo vaše saopštenje za javnost!

Losartan lijek za visok krvni pritisak je sada povučen

Napisao urednik

Mint Pharmaceuticals Inc. povlači sve serije svojih tableta losartana na recept, u ​​jačinama od 50 mg i 100 mg, nakon što su testovi otkrili azido nečistoću (5-(4′-((5-(azidometil)-2-butil-4-hloro -1H imidazol-1-il)metil)-[1,1′-bifenil]-2-il)-1H tetrazol) iznad prihvatljive granice. Dugotrajno izlaganje nečistoći na nivoima iznad onoga što se smatra sigurnim može potencijalno povećati rizik od raka.

Print friendly, PDF i e-pošta

Molimo pogledajte kompletan savjet za više informacija, uključujući šta bi Kanađani trebali učiniti i rad Health Canada na rješavanju problema azido nečistoća koje se nalaze u određenim lijekovima.

ProizvodKompanijaIZmnogoIstek
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETEMint Pharmaceuticals Inc.023896572005006959April 2023
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETEMint Pharmaceuticals Inc.023896572005006960April 2023
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETEMint Pharmaceuticals Inc.023896572005006961April 2023
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETEMint Pharmaceuticals Inc.023896572005006962April 2023
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETEMint Pharmaceuticals Inc.023896572005006963April 2023
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETEMint Pharmaceuticals Inc.023896572005011154Juni 2023
MINT-LOSARTAN/HCTZ 50/12.5 mg TABLETEMint Pharmaceuticals Inc.023896572005011156Juni 2023
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETEMint Pharmaceuticals Inc.023896652005006807April 2022
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETEMint Pharmaceuticals Inc.023896652005006808April 2022
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETEMint Pharmaceuticals Inc.023896652005006809April 2022
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETEMint Pharmaceuticals Inc.023896652005006810April 2022
MINT-LOSARTAN/HCTZ 100/12.5 mg TABLETE Mint Pharmaceuticals Inc.023896652105002149Decembar 2022
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896731805012687Oktobar 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896731805012688Oktobar 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896731805012689Oktobar 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896731805012792Oktobar 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896731905001010Decembar 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETE Mint Pharmaceuticals Inc.023896731905001011Decembar 2021
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896732005006947April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896732005006949April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896732005006950April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896732005006951April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETE Mint Pharmaceuticals Inc.023896732005007297April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896732005007298April 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896732005013776avgust 2023
MINT-LOSARTAN/HCTZ DS 100/25 mg TABLETEMint Pharmaceuticals Inc.023896732105002150Decembar 2023
Print friendly, PDF i e-pošta

O autoru

urednik

Glavna urednica je Linda Hohnholz.

Ostavite komentar